Trastuzumab-MCC-DM1 shows potent activity in both Trastuzumab-insensitive and Trastuzumab-sensitive cancers versions with overexpressed HER2 [119]. tyrosine kinase activity, and interruption from the downstream sign pathway will be summarized. For the targeted medication delivery to HER2 positive tumor cells, several targeting ligands and their delivery systems will be defined in information. Copyright authorization will be requested.) […]